Stifel Nicolaus Increases Zimmer Biomet (NYSE:ZBH) Price Target to $118.00

Zimmer Biomet (NYSE:ZBH) had its price target lifted by equities research analysts at Stifel Nicolaus from $115.00 to $118.00 in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Stifel Nicolaus’ target price indicates a potential upside of 17.96% from the company’s current price.

ZBH has been the subject of several other reports. UBS Group lifted their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a report on Friday, August 8th. Evercore ISI cut their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a report on Tuesday, July 8th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research report on Thursday. Royal Bank Of Canada raised their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Finally, Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet has a consensus rating of “Moderate Buy” and an average target price of $113.16.

Zimmer Biomet Stock Down 0.2%

ZBH stock opened at $100.03 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet has a 52 week low of $89.22 and a 52 week high of $114.72. The firm has a 50 day moving average of $100.06 and a 200 day moving average of $99.39. The stock has a market capitalization of $19.82 billion, a PE ratio of 24.34, a price-to-earnings-growth ratio of 2.30 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same period in the previous year, the business posted $2.01 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current year.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.39% of the stock is owned by insiders.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after purchasing an additional 198,370 shares in the last quarter. Dodge & Cox increased its stake in Zimmer Biomet by 12.9% in the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the last quarter. American Century Companies Inc. increased its stake in Zimmer Biomet by 8.7% in the second quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after purchasing an additional 458,903 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 1.4% in the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after acquiring an additional 69,485 shares during the period. Finally, Primecap Management Co. CA boosted its holdings in shares of Zimmer Biomet by 0.6% in the second quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after acquiring an additional 27,860 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.